Compositions and methods of treating muscle atrophy and myotonic dystrophy
Andrew John Geall, Carlsbad, CA (US); Venkata Doppalapudi, San Diego, CA (US); David Sai-Ho Chu, La Jolla, CA (US); Michael Caramian Cochran, La Jolla, CA (US); Michael Hood, San Diego, CA (US); Beatrice Diana Darimont, San Diego, CA (US); Rob Burke, Encinitas, CA (US); Yunyu Shi, San Diego, CA (US); Gulin Erdogan Marelius, San Diego, CA (US); and Barbora Malecova, La Jolla, CA (US)
Assigned to AVIDITY BIOSCIENCES, INC., San Diego, CA (US)
Filed by Avidity Biosciences, Inc., San Diego, CA (US)
Filed on Nov. 17, 2022, as Appl. No. 18/056,664.
Application 17/464,607 is a division of application No. 17/024,624, filed on Sep. 17, 2020, granted, now 11,253,607, issued on Feb. 22, 2022.
Application 18/056,664 is a continuation of application No. 17/464,607, filed on Sep. 1, 2021, granted, now 11,554,176.
Application 17/024,624 is a continuation of application No. 16/435,422, filed on Jun. 7, 2019, granted, now 10,881,743, issued on Jan. 5, 2021.
Application 16/435,422 is a continuation of application No. PCT/US2018/064359, filed on Dec. 6, 2018.
Claims priority of provisional application 62/725,883, filed on Aug. 31, 2018.
Claims priority of provisional application 62/595,545, filed on Dec. 6, 2017.
Prior Publication US 2023/0201363 A1, Jun. 29, 2023
1. An antisense oligonucleotide (ASO)-antibody conjugate comprising an anti-transferrin receptor antibody or antigen-binding fragment thereof conjugated to an ASO that hybridizes to a target sequence of human Murf1 mRNA and mediates RNA interference against the human Murf1 mRNA in a muscle cell, and wherein the ASO comprises a sequence selected from SEQ ID NOs: 651-702.